JP2024515066A5 - - Google Patents

Info

Publication number
JP2024515066A5
JP2024515066A5 JP2023562162A JP2023562162A JP2024515066A5 JP 2024515066 A5 JP2024515066 A5 JP 2024515066A5 JP 2023562162 A JP2023562162 A JP 2023562162A JP 2023562162 A JP2023562162 A JP 2023562162A JP 2024515066 A5 JP2024515066 A5 JP 2024515066A5
Authority
JP
Japan
Prior art keywords
acid sequence
amino acid
seq
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023562162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515066A (ja
JP7829595B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/053334 external-priority patent/WO2022215054A1/en
Publication of JP2024515066A publication Critical patent/JP2024515066A/ja
Publication of JP2024515066A5 publication Critical patent/JP2024515066A5/ja
Application granted granted Critical
Publication of JP7829595B2 publication Critical patent/JP7829595B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023562162A 2021-04-09 2022-04-08 補体因子dを標的とする抗体及びその使用 Active JP7829595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163173092P 2021-04-09 2021-04-09
US63/173,092 2021-04-09
PCT/IB2022/053334 WO2022215054A1 (en) 2021-04-09 2022-04-08 Antibodies targeting complement factor d and uses therof

Publications (3)

Publication Number Publication Date
JP2024515066A JP2024515066A (ja) 2024-04-04
JP2024515066A5 true JP2024515066A5 (https=) 2025-02-18
JP7829595B2 JP7829595B2 (ja) 2026-03-13

Family

ID=81307899

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562162A Active JP7829595B2 (ja) 2021-04-09 2022-04-08 補体因子dを標的とする抗体及びその使用

Country Status (5)

Country Link
US (1) US20240034779A1 (https=)
EP (1) EP4320149A1 (https=)
JP (1) JP7829595B2 (https=)
CN (1) CN117425673A (https=)
WO (1) WO2022215054A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025045251A2 (en) * 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Multispecific constructs comprising anti-factor d moiety
CN119001117A (zh) * 2023-09-05 2024-11-22 中国医学科学院北京协和医院 检测aagn标志物plg蛋白的试剂的应用
WO2025208782A1 (en) * 2024-04-02 2025-10-09 Linno (Hangzhou) Pharmaceuticals Inc. Cfd-binding antibody fragments and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
JP4437192B2 (ja) 1998-02-20 2010-03-24 タノックス インコーポレイテッド 補体活性化阻害剤
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
DE60135352D1 (de) 2000-08-30 2008-09-25 Univ Johns Hopkins Vorrichtung zur intraokularen wirkstoffverabreichung
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
WO2003022330A2 (en) 2001-09-12 2003-03-20 Becton, Dickinson And Company Microneedle-based pen device for drug delivery and method for using same
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20040102469A1 (en) 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
US20060167435A1 (en) 2003-02-18 2006-07-27 Adamis Anthony P Transscleral drug delivery device and related methods
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
TW201716437A (zh) 2006-11-02 2017-05-16 建南德克公司 人類化之抗-因子d抗體及其用途
JP2010533181A (ja) 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド TNFα阻害剤の肺投与のための方法及び組成物
JP5932670B2 (ja) 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション pH依存性の抗原結合を有する抗体
EP2622074B1 (en) 2010-09-30 2014-11-12 Board Of Trustees Of Northern Illinois University Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
AU2015253042A1 (en) * 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
AU2018217720A1 (en) 2017-02-10 2019-09-05 The Trustees Of The University Of Pennsylvania Anti-factor D antibodies and uses thereof
CA3059938A1 (en) * 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
CN110240652B (zh) 2019-06-05 2022-09-06 百奥泰生物制药股份有限公司 抗补体d因子抗体及其应用

Similar Documents

Publication Publication Date Title
TWI848905B (zh) 用於治療補體介導之疾病及病症之方法
JP2024515066A5 (https=)
JP6224059B2 (ja) 補体のインヒビターによる発作性夜間血色素尿症患者の処置
US9861696B2 (en) Monoclonal antibodies for Ebola and Marburg viruses
AU2022215307B2 (en) Methods of treating autoimmune and alloimmune disorders
JP6278536B2 (ja) 関節炎治療
JP4694784B2 (ja) 慢性関節炎の処置
JP6105146B2 (ja) Pan−ELR+CXCケモカイン抗体
JP2010100662A (ja) 補体成分c5に対する抗体を使用する喘息の処置の方法
JP2018535948A5 (https=)
CN107207588A (zh) 针对tau的抗体和其用途
JP2020521745A (ja) 治療用抗cd40リガンド抗体
JP2020535151A (ja) 病気の症状の治療又は予防に使用するための抗アドレノメデュリン(adm)バインダー
WO2021250533A1 (en) Methods of treatment using omalizumab or ligelizumab
BR112020017445A2 (pt) anticorpos anti cd6 para tratar asma severa
JP2023537078A5 (https=)
US20020081300A1 (en) Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
Dinov et al. Current and emerging therapies for autoimmune encephalitis
Wang et al. Therapeutic strategies targeting complement in myasthenia gravis patients
Wegmüller Effect of intravenous immunoglobulin therapy on plasma complement
WO2025218746A1 (en) Methods of treating rheumatoid arthritis
WO2023246570A1 (zh) 白介素-9的抗体及其用途
HK40120923A (zh) 用於治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂
TW202513582A (zh) 過敏疾病的預防或治療藥
CN117866092A (zh) 抗人cd73抗体或其抗原结合片段及其应用